Table 1.

Demographic and clinical features of patients at the time of diagnosis of lupus myocarditis compared to a healthy non-lupus control group.

	Lupus myocarditis group	Healthy control group
	n/total (%)	n/total (%)
Female gender	26/28 (92.9)	26/28 (92.9)
Ethnicity: mixed racial ancestry	25/28 (89.3)	25/28 (89.3)
Age (years) mean ± s.d.	28.32 ± 11.35	28.48 ± 11.33
Duration of SLE (weeks) median (IQR)	11.5 (IQR: 0–119)
SLEDAI median (IQR)	17.5 (IQR: 12.3–24)
Lupus nephritis	19 (67.9)
Co-morbidities
Antiphospholipid syndrome	1/28 (3.6)	0/28 (0)
Hypertension	7/28 (25)	0/28 (0)
Diabetes mellitus	1/28 (3.6)	0/28 (0)
Dyslipidemia	2/28 (7.1)	0/28 (0)
Clinical features of lupus myocarditis
Symptoms
New York Heart Association class 3/more dyspnea	21/23 (91.3)
Orthopnoea/paroxysmal nocturnal dyspnea	6/28 (21.4)
Palpitations	1/28 (3.6)
Chest pain	2/28 (7.1)
Signs
Respiratory crackles/pulmonary edema	24/28 (85.7)
Pleural effusion	9/28 (32.1)
Raised jugular venous pressure	7/28 (25)
Displaced apex	8/28 (28.6)
Tachycardia	26/28 (92.9)
New murmur	1/28 (3.6)
S3 gallop	11/28 (39.3)
Pedal edema	12/28 (42.9)

IQR, inter quartile range; s.d., standard deviation; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.